Inclusion Criteria:

- Planned chemotherapy treatment - Anemia (hemoglobin concentration
less than or equal to 11.0 g/dL) - Adequate renal and liver function - Subjects must
provide written informed consent Exclusion Criteria: - Known history of seizure disorder -
Known primary hematologic disorder causing anemia other than non-myeloid malignancies -
Unstable / uncontrolled cardiac condition - Clinically significant inflammatory disease -
Known positive test for HIV infection - Neutralizing antibodies to rHuEPO - Epoetin alfa
or darbepoetin alfa therapy within 4 weeks before randomization - Received any
investigational drug or device within 30 days before randomization - Pregnant or breast
feeding - Not using adequate contraceptive precautions - Previously randomized into this
study - Known hypersensitivity to recombinant mammalian-derived product - Concerns for
subject's compliance